The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...

ICER's evaluation of Vertex Pharmaceuticals' non-opioid pain drug, Journavx, finds cost-effectiveness related to potential ...

Vertex Software faces strong competition and slower growth, leading to a neutral rating. See why VERX stock remains pricey ...

BofA raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $567 from $555 and keeps a Buy rating on the shares. After having ...

The forward-looking statements contained in this Press Release are based on the expectations, estimates and projections of management of Vertex as of the date of this Press Release unless ...

Zimislecel, Vertex’s investigational fully differentiated islet cell therapy with standard immunosuppression, is in the Phase 3 portion of the Phase 1/2/3 study in patients with T1D with severe ...

Vertex AI Search for healthcare's new, multimodal search capabilities can help organizations give doctors, nurses, and others a more comprehensive view of patient health. Google Cloud Logo ...

EasyPark Group, a leading provider of digital parking and mobility solutions, and Google Cloud today announced a strategic collaboration to support its multicloud strategy and advance its AI journey.

The Israeli spyware company blacklisted over human rights concerns has hired the firm to provide strategic advice on cyber policy issues.

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...

Nonprofit organizations utilizing the latest ezCheckprinting and virtual printer software no longer need be concerned about ...

In December 2023, through the development efforts of CRISPR Therapeutics and Vertex Pharmaceuticals ... Orkin and others in his group showed that removing BCL11A from developing red blood cells ...